Table 3 Baseline patient characteristics

Treatment

Cetuximab + irinotecan (%)

47 (96)

19 (90)

10 (83)

P = 0.212^†

Cetuximab monotherapy (%)

2 (4)

2 (10)

2 (17)

Age

Median (range)

61 (29–78)

65 (51–80)

65 (43–76)

P = 0.605^‡

Gender

Male (%)

31 (63)

16 (76)

6 (50)

P = 0.312^†

Female (%)

18 (37)

5 (24)

6 (50)

ECOG PS

0 (%)

34 (69)

13 (62)

5 (42)

P = 0.185^†

1–2 (%)

15 (31)

8 (38)

7 (58)

Primary lesion

Colon (%)

28 (57)

15 (71)

9 (75)

P = 0.416^†

Rectum (%)

21 (43)

6 (29)

3 (25)

Site of Metastasis

Liver

Yes (%)

33 (67)

13 (62)

8 (67)

P = 0.945^†

No (%)

16 (33)

8 (38)

3 (33)

Lung

Yes (%)

34 (69)

15 (71)

9 (75)

P = 1.000^†

No (%)

15 (31)

6 (29)

3 (25)

Lymph node

Yes (%)

26 (53)

7 (33)

9 (75)

P = 0.068^†

No (%)

23 (47)

14 (67)

3 (25)

Peritoneum

Yes (%)

11 (22)

3 (14)

2 (17)

P = 0.791^†

No (%)

38 (78)

18 (86)

9 (83)

No. of metastatic sites

1 (%)

9 (18)

9 (42)

3 (25)

P = 0.106^†

>2 (%)

40 (82)

12 (58)

9 (75)

Prior chemotherapy

Fluoropyrimidine

Refractory (%)

49 (100)

21 (100)

12 (100)

Intolerant (%)

0 (0)

0 (0)

0 (0)

Oxaliplatin

Refractory (%)

40 (82)

10 (48)

9 (75)

P = 0.017^†

Intolerant (%)

9 (18)

11 (52)

3 (25)

Irinotecan

P = 1.000^†

Refractory (%)

48 (98)

21 (100)

12 (100)

Intolerant (%)

1 (2)

0 (0)

0 (0)

P = 0.669^†

Before bevacizumab therapy

25 (51)

9 (43)

7 (58)

Yes (%)

24 (49)

12 (57)

5 (42)

P = 0.236^†

No (%)

12

5

25

Response rate for prior irinotecan-containing therapies (%)

Pathological classification

G1, G2 (%)

42 (86)

20 (95)

11 (92)

P = 0.481^†

G3, G4 (%)

7 (14)

1 (5)

1 (8)